Quality-Adjusted Survival in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox Alone

J. Wang(RTI Health Solutions), Jean‐Yves Douillard(Integrated Oncology (United States)), S. Braun(Amgen (Switzerland)), Brittany Barber(Amgen (United States)), Martin Gallagher(The George Institute for Global Health), Zhongyun Zhao(Amgen (United States)), R. Sidhu(Amgen (United States)), Beth Sherrill(RTI Health Solutions), J. Zhang(RTI Health Solutions)
Annals of Oncology
September 1, 2012
10.1016/s0923-7534(20)33174-4
Cited by 0

Related Papers

Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
|The Lancet Oncology|2014|948
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609